| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Unité de Défense Innée et Inflammation, Institut National de la Santé et de la Recherche Médicale, Equipe 336, Institut Pasteur, Paris, France;
Plateforme de Protéomique, Institut Pasteur, Paris, France;
Klinische Forschergruppe der Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, München, Germany; and
Medizinisches Fachlabor Bautzen, Bautzen, Germany
The urokinase receptor (CD87) participates to the pericellular proteolytic potential of migrating cells and to the recruitment of leukocytes during inflammation. It consists of three structurally homologous domains, with the C-terminal domain D3 attached to cell membranes through a GPI anchor. CD87 is susceptible to an endoproteolytic processing removing the N-terminal domain D1 and generating truncated D2D3 membrane species, thus modulating CD87-associated functions. Full-length or truncated CD87 can be also released from cells via juxtamembrane cleavage by phospholipases and/or by yet unidentified proteinases. Using a recombinant CD87 and the CD87-positive monocytic U937 cell line and isolated blood monocytes, we show by protein immunoblotting and flow immunocytometry that the human neutrophil serine-proteinases elastase and cathepsin G cleave CD87 within the D1-D2 linker sequence, while in addition cathepsin G is highly efficient in cleaving the C terminus of D3. The combination of cathepsin G and elastase provided by degranulated neutrophils results in enzymatic cooperation leading to the release from monocytic cells of a truncated D2D3 species resembling that previously described in pathological body fluids. Using mass spectrometry analysis, the proteolytic fragmentation of synthetic peptides mapping the D1-D2 linker and D3 C-terminal domains identifies potential cleavage sites for each enzyme and suggests the existence of a mechanism regulating the CD87(D1-D2)-associated chemotactic activity. Finally, isolated or combined elastase and cathepsin G drastically reduce the capacity of cells to bind urokinase. Secretable leukocyte serine-proteinases are thus endowed with high potential for the regulation of CD87 expression and function on inflammatory cells.
This article has been cited by other articles:
|
|
 |
|
  S. F. Kingsmore, N. Kennedy, H. L. Halliday, J. C. Van Velkinburgh, S. Zhong, V. Gabriel, J. Grant, W. D. Beavis, V. T. Tchernev, L. Perlee, et al. Identification of Diagnostic Biomarkers for Infection in Premature Neonates Mol. Cell. Proteomics, October 1, 2008; 7(10): 1863 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Leduc, N. Beaufort, S. de Bentzmann, J.-C. Rousselle, A. Namane, M. Chignard, and D. Pidard The Pseudomonas aeruginosa LasB Metalloproteinase Regulates the Human Urokinase-Type Plasminogen Activator Receptor through Domain-Specific Endoproteolysis Infect. Immun., August 1, 2007; 75(8): 3848 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Bernstein, S. S. Twining, D. J. Warejcka, E. Tall, and S. K. Masur Urokinase Receptor Cleavage: A Crucial Step in Fibroblast-to-Myofibroblast Differentiation Mol. Biol. Cell, July 1, 2007; 18(7): 2716 - 2727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beaufort, D. Leduc, H. Eguchi, K. Mengele, D. Hellmann, T. Masegi, T. Kamimura, S. Yasuoka, F. Fend, M. Chignard, et al. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1263 - L1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Piironen, A. Haese, H. Huland, T. Steuber, I. J. Christensen, N. Brunner, K. Dano, G. Hoyer-Hansen, and H. Lilja Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in Serum Clin. Chem., May 1, 2006; 52(5): 838 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fietz, K. Hattori, E. Thiel, and B. Heissig Increased soluble urokinase plasminogen activator receptor (suPAR) serum levels after granulocyte colony-stimulating factor treatment do not predict successful progenitor cell mobilization in vivo Blood, April 15, 2006; 107(8): 3408 - 3409. [Full Text] [PDF]
|
|
|
|
|
|
R. Mazzieri, S. D'Alessio, R. K. Kenmoe, L. Ossowski, and F. Blasi An Uncleavable uPAR Mutant Allows Dissection of Signaling Pathways in uPA-dependent Cell Migration Mol. Biol. Cell, January 1, 2006; 17(1): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Selleri, N. Montuori, P. Ricci, V. Visconte, M. V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization Blood, March 1, 2005; 105(5): 2198 - 2205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Piironen, B. Laursen, J. Pass, K. List, H. Gardsvoll, M. Ploug, K. Dano, and G. Hoyer-Hansen Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor Clin. Chem., November 1, 2004; 50(11): 2059 - 2068. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
